South Korea has been and remains one of Bioengineering’s most important markets globally. Bioengineering was involved in several important milestone projects in the past. The first Asian FDA-approved animal cell culture pharmaceutical production facility was established by one of Bioengineering’s partners, the extension plant which went on to become the world’s first EMA-licensed biosimilar mAb. Another two-part facility became the world’s largest single bioproduction plant. Read more about these projects in our Praxis publications, Celltrion and Samsung.

Being closer to our customers allows us to understand specific requirements and concerns better, communicating in the local language and being faster. In addition we will provide additional expertise, partnered innovation, enhanced service, support and emergency stock locally. The branch office will start with three experienced employees, two Service Engineers and one Sales Manager.